【作者】 魏华萍；

【导师】 张铀； 杨玲；

【作者基本信息】 昆明医学院 ， 内科学， 2004， 硕士

【摘要】 [目的]研究MUC1粘蛋白分子在血液系统恶性肿瘤患者中的表达，探讨MUC1在血液系统恶性肿瘤中的作用机制、临床意义及在肿瘤生物治疗中的应用前景。 [方法]应用免疫组织化学及免疫细胞化学SP法检测了77例血液系统恶性肿瘤患者的骨髓、淋巴结及其他组织标本中MUC1粘蛋白的表达，并分析了与一些临床指标的关系。 [结果]9例多发性骨髓瘤(MM)患者MUC1阳性表达率(90％)和19例急性髓性白血病(AML)阳性表达率(63.2％)均高于对照组(10％)(P＜0.05)。26例B细胞性恶性肿瘤患者MUC1阳性表达率(73％)明显高于对照组(P＜0.05)。17例T细胞性恶性肿瘤均为阴性，和B细胞性恶性肿瘤组相比差异有显著性(P＜0.05)。在AML中MUC1高表达与患者的年龄及髓外浸润呈正相关，而与患者的性别、白细胞计数、乳酸脱氢酶含量及缓解率无明显相关。 [结论]MUC1粘蛋白在B细胞性恶性肿瘤特别是多发性骨髓瘤及急性髓性白血病中以非糖基化的形式表达异常增高，并与患者年龄、骨髓浸润呈正相关，提示MUC1在血液系统恶性肿瘤的发病中可能起一定的作用，其表达与MM、AML的病情进展及预后相关。为MUC1免疫原作为疫苗应用于血液系统恶性肿瘤生物治疗的研究提供一定的理论依据。更多还原

【Abstract】 [Objective]To detect MUC1 expression in the cases of hematoiogical malignant diseases and its clinical significance in these diseases, especially its targeting immunotherapeutic potency in these diseases. [Methods] The expression of MUC1 in the bone marrow, lymph nodes, and other tissues was assayed by immunocytochemical and immunohistochemical SP methods in total 77 cases of hematoiogical malignant diseases. The association between the expression of MUC1 and some clinic parameters was also analysised.[Results]The expression of MUC1 in AML and B cell malignant lymphoproliferative diseases especially in MM was significantly higher than that in normal blood cells (P<0.05). An analysis of correlation between the expression of MUC1 and other clinic parameters showed that increased MUC1 antigen expression was associated with some poor prognostic factors such as extramedullary infiltration and the age of older than 60-year-old patients with AML.[Conclusion] Our study showed that MUC1 was overexpressed in non-glycosylated form in AML and B cell malignant lymphoproliferativediseases, particularly in MM, and was associated with extramedullary infiltration as well as the age of older than 60-year-old patient with AML. MUC1 may be used as a poor prognostic factor in some malignant diseases. More importantly, it could be used as a immunotherapeutic methods for these diseases.更多还原